Cheapest Wegovy Discount Code - UK Price From £69.00

Our Pricing

Wegovy UK Discount Codes: £79.00 With WEIGHTLOSSNEW

Published on: June 03, 2026

Searching for a wegovy discount code uk to make semaglutide weight loss treatment more affordable? At Cured Pharmacy, use code WEIGHTLOSSNEW to access Wegovy from £79.00 — the lowest guaranteed price in the UK. Our transparent pricing, UK-registered prescribers, and discreet next-day delivery make starting your weight loss journey straightforward and affordable.

How the Wegovy Discount Code Works at Cured Pharmacy

The WEIGHTLOSSNEW discount code reduces your Wegovy prescription cost to £79.00, down from the standard £79.00. This promotional offer applies automatically during checkout when you complete your free online consultation with our UK-registered clinical team. Unlike other pharmacies that hide fees until the final step, we display your exact cost upfront — before you begin the assessment.

Your discounted Wegovy price includes the medication, clinical consultation with a UK prescriber, discreet packaging, and tracked delivery to your door. There are no hidden consultation fees, no subscription traps, and no pressure to commit beyond your initial prescription. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription dispensed from our GPhC-registered pharmacy (9012511), ensuring you receive genuine UK-licensed semaglutide pens every time.

Why Wegovy Costs Less at Cured Pharmacy

We've structured our pharmacy to eliminate the markup layers that inflate prices elsewhere. By operating exclusively online, we avoid the overhead costs of high-street premises and pass those savings directly to you. Our pricing model is transparent: you see the £79.00 cost before starting your consultation, and that figure never changes at checkout.

Many UK pharmacies advertise low starting prices but add consultation fees, delivery charges, or mandatory subscription renewals that push the true cost significantly higher. At Cured Pharmacy, the price you see is the price you pay. We guarantee the lowest Wegovy prices in the UK — if you find a lower legitimate price from another GPhC-registered pharmacy, we'll match it.

Transparent Pricing vs Hidden Fees

Traditional pharmacy pricing often obscures the real cost until you've invested time in consultations and paperwork. We believe patients deserve honesty from the start. Our £79.00 Wegovy price includes everything: the semaglutide pen, prescriber review, pharmacy dispensing, and delivery. No surprises, no additional charges, no fine print.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your gut releases after eating. This medication works through three complementary mechanisms: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves insulin sensitivity to help regulate blood sugar [1]. Unlike stimulant-based weight loss pills, semaglutide doesn't artificially speed up your metabolism — it recalibrates your body's natural hunger and satiety signals.

In the landmark STEP 1 clinical trial, adults using Wegovy alongside lifestyle modifications achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Participants reported sustained appetite suppression and improved eating behaviour without the jitteriness or sleep disruption associated with older weight loss medications. The MHRA licensed Wegovy specifically for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [2].

Clinical Evidence Behind Semaglutide

The STEP trial programme represents the most comprehensive evaluation of semaglutide for weight management, involving over 4,500 participants across multiple countries. STEP 2 specifically examined patients with type 2 diabetes, demonstrating that semaglutide produced superior weight loss compared to existing GLP-1 treatments while simultaneously improving glycaemic control [2]. These results led NICE to recommend Wegovy as a specialist weight management option within the NHS framework, subject to specific eligibility criteria.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a carefully structured dose escalation schedule designed to minimise gastrointestinal side effects while your body adjusts to semaglutide. You'll start with 0.25 mg once weekly for four weeks, then increase to 0.5 mg for four weeks, followed by 1.0 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg [3]. Each injection is administered subcutaneously using a pre-filled pen — most patients choose the abdomen, thigh, or upper arm as injection sites.

The gradual titration schedule exists for good reason: starting at the full 2.4 mg dose would likely cause significant nausea, vomiting, and diarrhoea. By increasing slowly, most patients experience only mild, transient digestive symptoms that resolve within the first few weeks. Your UK prescriber will monitor your progress throughout the escalation phase and may adjust the timeline if you experience persistent side effects. Clinical trials showed that 74% of participants reached the full 2.4 mg maintenance dose successfully [3].

Common Side Effects and How to Manage Them

Gastrointestinal effects are the most frequently reported side effects with Wegovy, affecting approximately 44% of users in clinical trials [1]. Nausea typically peaks during the first few weeks after each dose increase, then subsides as your body adapts. Other common effects include diarrhoea, constipation, abdominal pain, and occasional vomiting. These symptoms are generally mild to moderate and rarely lead to treatment discontinuation when managed appropriately.

Practical strategies can significantly reduce digestive discomfort: eat smaller, more frequent meals rather than large portions; avoid high-fat and heavily processed foods that slow digestion further; stay well-hydrated throughout the day; and inject Wegovy on the same day each week to maintain consistent drug levels. If nausea persists beyond the first month at a given dose, contact your prescriber — they may recommend staying at your current dose longer before escalating, or prescribing a short course of anti-nausea medication.

Serious side effects are rare but require immediate medical attention. These include severe abdominal pain that doesn't resolve (potential pancreatitis), changes in vision, signs of thyroid tumours (lump in the neck, persistent hoarseness), or symptoms of gallbladder problems [4]. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans. Your prescriber will review your personal and family medical history to ensure semaglutide is appropriate for you.

When to Contact Your Prescriber

Most side effects improve with time and simple dietary modifications, but certain symptoms warrant clinical review. Contact your UK prescriber if you experience persistent vomiting that prevents you from keeping down fluids, severe abdominal pain, signs of an allergic reaction (rash, swelling, difficulty breathing), or if you're unable to tolerate the medication despite supportive measures. Never adjust your dose or stop treatment without consulting a healthcare professional, as abrupt discontinuation can affect your weight management progress.

Who Can Use Wegovy and Eligibility Criteria

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related health condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. The medication is intended as an adjunct to a reduced-calorie diet and increased physical activity, not a standalone solution. Your UK prescriber will calculate your BMI during the online consultation and assess whether you meet the clinical criteria for treatment.

Certain medical conditions preclude Wegovy use. You cannot take semaglutide if you have a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or if you've had a serious allergic reaction to semaglutide or any ingredient in Wegovy [4]. Women who are pregnant, planning pregnancy, or breastfeeding should not use this medication, as animal studies suggest potential foetal harm. Your prescriber will review your complete medical history, current medications, and any allergies before approving your prescription.

Age restrictions apply: Wegovy is licensed only for adults aged 18 and over in the UK. While semaglutide has been studied in adolescents aged 12-17 in other countries, it does not currently hold a UK licence for paediatric weight management. If you're taking other medications — particularly insulin, sulfonylureas, or other diabetes medications — your prescriber may need to adjust those doses to prevent hypoglycaemia when starting Wegovy.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2022). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/ [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to lifestyle modifications alongside medication use.